← Back to Search

Sulforaphane for Lung Cancer

Phase 2
Waitlist Available
Led By Jian-Min Yuan, MD, PhD
Research Sponsored by Jian-Min Yuan, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Study Summary

This trial will test whether the dietary supplement Sulforaphane can help prevent lung cancer in people who are at high risk due to their smoking history.

Eligible Conditions
  • Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Caspase-3
Bronchial dysplasia index
Cell proliferation marker Ki-67
Secondary outcome measures
Bronchial Pre-malignant lesions
Gene Expression
Gene Expression Nasal Epithelia
+1 more

Side effects data

From 2013 Phase 2 trial • 20 Patients • NCT01228084
35%
Flatulence
35%
Nausea
20%
Bloating
20%
Diarrhea
20%
Dyspepsia
15%
Gatrointestinal pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Sulpforaphane

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Sulforaphane (Study Drug)Experimental Treatment1 Intervention
Sulforaphane four tablets 2 times per day with breakfast and dinner each dose contains approximately 120 micromole of Sulforaphane
Group II: PlaceboPlacebo Group1 Intervention
Placebo (containing no active drug) four tablets 2 times per day with breakfast and dinner
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sulforaphane
2016
Completed Phase 3
~550

Find a Location

Who is running the clinical trial?

Jian-Min Yuan, MDLead Sponsor
National Cancer Institute (NCI)NIH
13,671 Previous Clinical Trials
40,926,702 Total Patients Enrolled
Jian-Min Yuan, MD, PhDPrincipal Investigator - Univesity of Pittsburgh
University of Pittsburgh

Media Library

Placebo Clinical Trial Eligibility Overview. Trial Name: NCT03232138 — Phase 2
Lung Cancer Research Study Groups: Sulforaphane (Study Drug), Placebo
Lung Cancer Clinical Trial 2023: Placebo Highlights & Side Effects. Trial Name: NCT03232138 — Phase 2
Placebo 2023 Treatment Timeline for Medical Study. Trial Name: NCT03232138 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the objective of this experiment?

"This clinical trial's primary objective is to gauge the Bronchial dysplasia index over a 12 month period. Additionally, Gene Expression and Bronchial Pre-malignant Lesions will be assessed as secondary objectives, with Number of Participants With Treatment-Related Adverse Events evaluated via CTCAE v4.0 for safety purposes."

Answered by AI

Is recruitment for this experiment still ongoing?

"This investigation, which was initially posted on the 25th day of January 2018 and last updated on the 28th day of September 2022, is not presently enrolling patients. Nonetheless, there are 1628 other studies actively seeking participants at this present time."

Answered by AI

Which demographic is most suitable for involvement in this experiment?

"For this clinical trial, 67 patients with lung cancer aged between 55 and 75 are being sought. Essential eligibility criteria include: a minimum of 30 pack-year smoking history (with 1 year abstention) for former smokers; White Blood Cell count ≥3000/mL; Total Bilirubin ≤1.5x ULN (Upper Limits of Normal); AST/ALT ≤2.5x ULN; BUN and Creatinine levels ≤1.5xULN; Negative serum pregnancy test within 72 hours before first dose of medication if applicable; Global Initiative for Chronic Obstructive Lung Disease Grade II or greater airflow obstruction"

Answered by AI

Could you provide insight into the potential risks associated with Sulforaphane usage?

"Sulforaphane has been rated a 2 on our safety scale, signifying that prior studies have provided evidence of its safety but not its efficacy."

Answered by AI

Does the age limit of 65+ preclude elderly patients from participating in this experiment?

"Per the formal prerequisites for entry into this clinical trial, individuals aged 55 to 75 are eligible."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Clinical Trial of Lung Cancer Chemoprevention With Sulforaphane in Former Smokers
Jian-Min Yuan, MD 2018. "Clinical Trial of Lung Cancer Chemoprevention With Sulforaphane in Former Smokers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03232138.
~9 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top